国际肿瘤学杂志

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (7): 444-448.doi: 10.3760/cma.j.issn.1673-422X.2018.07.013

• 综述 • 上一篇    

 黑色素瘤靶向治疗的耐药机制及其治疗策略

金兰,康晓静   

  1. 830001 乌鲁木齐，新疆医科大学研究生院（金兰）;新疆维吾尔自治区人民医院皮肤性病科（金兰、康晓静）
  • 出版日期:2018-07-08 发布日期:2018-07-31
  • 通讯作者: 康晓静，Email: drkangxj666@163.com E-mail:drkangxj666@163.com
  • 基金资助:

    新疆维吾尔自治区自然科学基金（2016D01C101）

Drug resistance mechanism and treatment strategy for targeted therapy of melanoma

Jin Lan, Kang Xiaojing   

  1. Postgraduate School of Xinjiang Medical University; Department of Dermatology and Venereology, People′s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
  • Online:2018-07-08 Published:2018-07-31
  • Contact: Kang Xiaojing, Email: drkangxj666@163.com E-mail:drkangxj666@163.com
  • Supported by:

    Natural Science Foundation of Xinjiang Uygur Autonomous Region of China (2016D01C101)

PDF

1311

摘要： 靶向药物的耐药问题在黑色素瘤的治疗中逐渐显现，目前已知的药物耐药机制包括丝裂原激活蛋白激酶（MAPK）通路再活化、MAPK旁路途径的激活、肿瘤微环境的影响、微小RNA的异常表达等。通过黑色素瘤靶向药物的联合应用、免疫联合治疗等策略可延缓耐药性的发生，延长患者的生存期。

关键词: 黑色素瘤, 抗药性, 肿瘤, 靶向治疗

Abstract: Drug resistance of targeted therapy gradually emerges in the treatment of melanoma. Currently known mechanisms of drug resistance include reactivation of mitogenactivated protein kinase (MAPK) pathway, activation of MAPK alternative pathway, effects of tumor microenvironment, and abnormal expression of microRNA. Through the combination of targeted drugs, immunological combination therapy and other strategies can delay the occurrence of drug resistance, thereby prolonging the survival of patients.

Key words: Melanoma, Drug resistance, neoplasm, Targeted therapy